• Users Online: 216
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 45  |  Issue : 3  |  Page : 129-134

Bortezomib in multiple myeloma: treatment response and survival outcome


Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt

Correspondence Address:
Eslam S.M Bassiony
Clinical Oncology, Faculty of Medicine, Tanta University, Tanta, 31511
Egypt
Login to access the Email id


DOI: 10.4103/tmj.tmj_21_17

Rights and Permissions

Background Bortezomib, a first-in-class proteasome inhibitor, was approved by the Food and Drug Administration in 2003. Bortezomib has come a long way since its development as one of the most effective drugs currently available for treating multiple myeloma. With improved efficacy of combination regimens, we have seen increasing use of its therapeutic spectrum ranging from frontline induction to maintenance therapy. Bortezomib has been integrated into the treatment of myeloma at every disease stage. Aim The aim of this study was to evaluate the disease response and survival outcome in patients with multiple myeloma who were treated with bortezomib as first-line or second-line treatment who had recurrent or refractory disease after systemic chemotherapy. Patients and methods This retrospective study included 23 patients with multiple myeloma who were treated at Clinical Oncology and Nuclear Medicine Department, Tanta University Hospital, Faculty of Medicine, Tanta University, and were diagnosed between January 2012 and January 2016. Nine patients received bortezomib as a first-line treatment, whereas 14 patients received it as a second-line treatment. Results Bortezomib shows better response rate and survival outcome especially in patients who received it as the first line of treatment. About 52.5% of patients show partial response or better response. Conclusion Bortezomib with dexamethasone gives a response rate and survival outcome better than conventional treatment, dexamethasone alone, or bortezomib single agent. However, bortezomib combination with other chemotherapeutic agents gives more response rate than bortezomib with dexamethasone.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed285    
    Printed14    
    Emailed0    
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal